Network News

Shield against metastases and genetically protected CAR-T cells: Double honor for Mirco Julian Friedrich

Physician and cancer researcher Mirco Julian Friedrich from the German Cancer Research Center (DKFZ), the stem cell research institute HI-STEM*, and Heidelberg University Hospital (UKHD) has received two awards for two independent research projects: The Beug Foundation has honored his novel approach to preventing liver metastases with the Metastasis Prize 2025. The Kind-Philipp Research Prize […]

Heidelberg Pharma Announces Changes to the Executive Management Board – Dr Dongzhou Jeffery Liu Appointed as Chairman of the Executive Board and Chief Executive Officer

Ladenburg, Germany, 24 November 2025 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced that the Supervisory Board has revoked the appointment of Professor Andreas Pahl as member of the Executive Management Board and Chief Executive Officer, and has instead appointed Dr Dongzhou Jeffery Liu as Chairman […]

Sanofi and Regeneron’s Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria

Sanofi and Regeneron’s Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria Paris and Tarrytown, NY, November 25, 2025. The European Commission has approved Dupixent (dupilumab) for the treatment of moderate-to-severe chronic spontaneous urticaria (CSU) in adult and adolescent patients 12 years and above with inadequate response […]

With a Humboldt Professorship to Universität Heidelberg

International research prize goes to immunologist Jan Rehwinkel as nominated by Ruperto Carola In order to boost the research field of immunology as a key biomedical discipline at Heidelberg University, Prof. Dr Jan Rehwinkel is receiving a Humboldt Professorship worth five million euros. Leading international academics are granted such a professorship to encourage them to […]

One device – two organs: Simultaneous perfusion opens up new possibilities for future multi-organ transplants

A key factor in the success of an organ transplant is the condition of the donated organ at the time of implantation. Preserving the organ prior to transplantation using machine perfusion plays a crucial role in this process. This procedure has now been implemented particularly efficiently at Heidelberg University Hospital (UKHD): as part of a […]

Award-winning: Concept for “the perfect stroke room”

UKHD wins DGN Nursing Award 2025 for its “Stroke Unit Innovation Room” project. Full Text in German below. Ausgezeichnet: Konzept für „das perfekte Schlaganfallzimmer“ UKHD gewinnt DGN-Pflegepreis 2025 für das Projekt „Innovationszimmer Stroke Unit“ Das Universitätsklinikum Heidelberg (UKHD) ist mit dem Pflegepreis der Deutschen Gesellschaft für Neurologie (DGN) ausgezeichnet worden. Prämiert wurde das Projekt „Innovationszimmer […]

FDA approves Promega OncoMate® MSI Dx Analysis System as a companion diagnostic for KEYTRUDA® in combination with LENVIMA® in advanced endometrial cancer

Promega’s MSI technology will help identify patients with microsatellite stable (MSS) endometrial cancer Full Text in German below. Die FDA genehmigt das Promega OncoMate® MSI Dx Analysis System als Begleitdiagnostikum für KEYTRUDA® in Kombination mit LENVIMA® bei fortgeschrittenem Endometriumkarzinom Die MSI-Technologie von Promega wird bei der Identifizierung von Patientinnen mit mikrosatellitenstabilem (MSS) Endometriumkarzinom helfen Madison, […]

$AbbVie Announces U.S. FDA Approval of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide for Relapsed or Refractory Follicular Lymphoma$

AbbVie Announces U.S. FDA Approval of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide for Relapsed or Refractory Follicular Lymphoma

NORTH CHICAGO, Ill., Nov. 18, 2025 /PRNewswire/ — AbbVie (NYSE: ABBV) today announced that EPKINLY® (epcoritamab-bysp), a T-cell engaging bispecific antibody administered subcutaneously, in combination with rituximab and lenalidomide (EPKINLY + R2) is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL). This approval of […]

Universität Heidelberg with 16 “Highly Cited Researchers”

International evaluation names researchers whose publications have been most cited worldwide 16 researchers from Heidelberg University feature on the recently published list of “Highly Cited Researchers”. This international evaluation names researchers whose publications have been cited most frequently worldwide in their respective field or who have an outstanding track-record of publications across several disciplines. The […]